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Abstract
Background: Wear-induced osteolysis is the main factor in reducing the longevity of total hip arthroplasty (THA).
The transmembrane Receptor Activator of Nuclear Factor κ B (RANK) and its corresponding ligand RANKL is an
important regulator of osteoclast activity and bone resorption and is associated with osteolysis around implant.
Inhibiting RANKL with denosumab is effective in vivo in preventing osteoporosis-related fractures. In vitro, osteoclasts
can be blocked in animal models of osteolysis. We hypothesize that denosumab is effective in reducing wear-induced
osteolysis around uncemented acetabular implants in THA.
Methods/design: A randomized, double-blind, placebo-controlled trial will be conducted. We will include 110
patients, 40–85 years of age, with a known osteolytic lesion around an uncemented acetabular component ≥7 years after
the primary operation. The patients will be randomized in a 1:1 ratio to subcutaneous injections of 60 mg denosumab or
placebo for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months. The primary
endpoint will be the change in volume of the osteolytic lesion at 3 years measured with three-dimensional computed
tomography (3D-CT). Secondary endpoints include functional outcome scores, change in bone mineral density of the
lumbar spine, serological markers of bone turnover and adverse events.
Discussion: In vitro results of both bisphosphonates and RANKL inhibitors have been promising, showing reduced
osteolysis with treatment. This is, to our knowledge, the first clinical trial testing the efficacy of denosumab in reducing
wear-induced osteolysis. The study is an academic, phase II trial from an independent center and is designed to
demonstrate efficacy in reducing volume of osteolytic lesions around a total hip arthroplasty.
Trial registration: ClinicalTrials.gov (NCT02299817) 2014-11-20
Keywords: Total hip arthroplasty, Osteolysis, Denosumab, Randomized clinical trial, Outcome, Computed tomography
Background
Total hip arthroplasty (THA) is one of the most cost-
effective [1] and quality of life restoring [2] surgical pro-
cedure in orthopaedics and more than 2 million patients
undergo THA worldwide annually. Although THA gener-
ally leads to remarkably good outcomes, more than 100
000 patients each year have to undergo a risky and costly
revision surgery due to aseptic loosening caused by oste-
olysis. This cell mediated inflammatory response to wear
debris from the artificial joint is the major factor in redu-
cing the longevity of a THA [3–5] The risk of failure is
highest in younger males with a 30 % risk for revision
surgery within 10 years [6, 7]. Despite continual changes
in surgical technique and implant design, the revision
THA burden (defined as the percentage of revision THA
cases as a function of all THA cases) has not decreased
over time and is currently around 10 % in Sweden and
17 % in the US [8, 9].
Osteolytic lesions around well-fixed orthopaedic implants
are notoriously difficult to detect and are, 7–14 years after
surgery, present in 10-70 % of hips [10, 11]. They are in
almost all cases asymptomatic and can only be detected
with a reasonably good sensitivity and specificity using
computed tomography (CT) or magnetic resonance tomog-
raphy [12]. The lesions typically occur more than 5 year
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after surgery [11] and, when extensive, undermine the bony
fixation of the implant thereby leading to loosening of the
artificial joint. The extent of the revision surgery and subse-
quent result for the individual patient is strongly correlated
to the size of the osteolytic lesion. There is little data on the
development and progression of osteolysis around hip im-
plants and there are few studies where osteolytic lesions
have been systematically followed over a number of years
using CT or MRI [13, 14].
The transmembrane Receptor Activator of Nuclear Fac-
tor κ B (RANK) and its corresponding ligand RANKL is
an important regulator of osteoclast activity and bone
resorption and is associated with osteolysis around im-
plants [15–17]. The wear particles from polyethylene in
the artificial joint induce the over-expression of RANK,
inflammatory cytokines interleukin (IL)-6, IL-8, interferon-
β-inducible protein (IP)-10, monocyte chemoattractant
protein (MCP)-1, monokine induced by interferon-β
(MIG) in the microenvironment around the implant [18].
This susceptibility to develop osteolysis has been shown to
vary between individuals [19, 20].
Bisphosphonates have been found to be effective in redu-
cing disuse bone atrophy (a.k.a. “stress-shielding”) around
orthopaedic implants but have not been effective in pre-
venting progress of osteolytic lesions [21, 22]. Cathepsin K
is a protease that is responsible for the degradation of bone
matrix by osteoclasts. Inhibitors of cathepsin K are in devel-
opment for treatment of osteoporosis and have recently
been show to reduce fracture risk in patients with osteopor-
osis [23]. The mechanism for Cathepsin K inhibitors could
potentially also be used for treatment of osteolysis; however,
there are currently no drugs available for use.
A MedLine search on the Mesh terms Osteolysis, Hip
Arthroplasty, Bisphosphonates, RANKL/RANK and Med-
ical treatment fails to find any studies on this subject and
in effect, there is as of yet no medical treatment available.
Recently denosumab was found to be effective in pre-
venting osteoporosis related fractures in post-menopausal
women [24] by blocking RANKL and thereby inhibiting
the development and activity of osteoclast. In a recently
published animal model of prosthetic loosening, targeting
osteoclast recruitment via RANKL inhibition was found
to be effective in targeting osteoclast [25]. Denosumab has
however, to the best of our knowledge, not been used to
try to prevent the progression of osteolysis and aseptic
loosening in THA.
The problem with osteolysis and subsequent loosening
around implants is equally pronounced for titanium hemi-
spherical acetabular components with polyethylene liners
as well as when the polyethylene is fixed to the host bone
with bone cement. In the U.S. and Europe titanium hemi-
spherical acetabular components with polyethylene liners
are the most common acetabular components and this
study will therefore aim to treat patients with these types of
implants. If denosumab is effective in treating osteolytic
lesions it would have an immense impact since revision
surgery is costly [26] and the results after surgery are
uncertain.
We hypothesize that denosumab is effective in reducing




A randomized, double-blind, placebo-controlled trial will
be conducted. Patients will be randomized in a 1:1 ratio
to placebo or denosumab using concealed envelopes. A
randomly assigned batch size of 4 to 10 (in increments
of 2; thus 4, 6, 8, or 10) will be used. Osteolytic lesion
volume (<10 cm3/≥10 cm3) at screening and physical
activity according to Johnston [27] (<4-low activity level/
≥4-high activity level) are clear risk factors for progression
of volume size and will therefore be used as stratification
to ensure that these are evenly distributed between the
two groups [13, 27, 28]. The patients and all staff and
investigators will be blinded to treatment. The study will
be carried out from 2015 to 2021 at the Orthopaedic
Department of Danderyd Hospital in collaboration with
the Karolinska Institute. The Ethics Committee of the
Karolinska Institute and the Swedish Medical Products
Agency approved the study. The trial is initiated, designed,
and performed as an academic investigation and regis-
tered at ClinicalTrials.gov (NCT02299817). The guidelines
of the CONSORT Statement will be followed [29].
Study population
Patients with titanium press-fit acetabular components
with polyethylene liners will be screened for osteolytic
lesions using three-dimensional computed tomography
(3D-CT). The patients had their primary surgery more
than 7 years before the screening and were all operated
because of osteoarthritis of the hip. This time period is
sufficient for osteolytic lesions to appear. In this patient
group we expect that approximately 30 % of screened
patients will have an osteolytic lesion. These patients with
screening-detected lesions as well as patients with previ-
ously known osteolytic lesions will be eligible for inclusion
in the study (Fig. 1). We will include asymptomatic pa-
tients, aged 40–85 years, with a primary THA performed
due to osteoarthritis or congenital dysplasia of the hip ≥
7 years before inclusion and who have a osteolytic lesion of
at least 4 cm3 and at most 40 cm3 around an uncemented
acetabular component with a polyethylene liner. Exclusion
criteria includes pain from the hip (VAS ≥3), any surgery of
the hip after index operation, ever use of bisphosphonates
and inflammatory arthritis. A detailed inclusion and exclu-
sion list is presented in Table 1. The inclusion period is
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planned from 2015 to 2016. End of study (EOS) will be at
the last included patient’s last visit.
Treatments
Half of the patients will receive a 1 ml subcutaneous
injection of denosumab 60 mg on day one and every
6 months with last treatment at 30 months (day 1, 6
mos., 12 mos., 18 mos., 24 mos., 30 mos.), total 6 times.
The other half will receive placebo injections as above. The
selected dose 60 mg is established in clinical routine for
treatment of osteoporosis. The syringes are to be stored at
2-8 °C in a locked, temperature controlled refrigerator. All
used syringes must be saved and stored in a cabinet to be
checked by the monitor. Study supplies will be documented
by completion of drug accountability forms. They will
include details of the quantities of IMP/placebo received,
administered, stored and dispatched or destroyed. Calcium
and Vitamin D (500 mg + 400 IE) twice daily will be given
from day 1 to 3 years to all patients. All personnel involved
in the study will be blinded. Code envelopes will be stored
at the investigator’s office to be used for emergency reasons.
In case of a suspected serious adverse drug reaction
(SADR) during the study, the PI will determine if unblind-
ing of the study drug is necessary. This decision will be
taken by the PI within 24 h of his knowledge of the event.
If the PI, for some reason, is unavailable, one of the co-
investigators will handle the decision of unblinding.
When and how to withdraw subjects from the trial
treatment
Patients with serious adverse events (SAE’s) with a direct
impact on the periprosthetic region studied will be
withdrawn from treatment. Examples of such SAE’s are
periprosthetic fractures after accidents, deep infections
with revision surgery or any kind of surgery in the hip
studied. Should a subject request or decide to withdraw
from the study, all efforts will be made to complete and
report the observations as thoroughly as possible up to the
date of withdrawal. For withdrawn subjects the last post-
baseline observation will be carried forward. If the subject
withdraws consent or is excluded from the study a 3D-CT
will be performed and serological bone turnover markers
will be collected (SCTx and P1NP). If implants are to be
revised during the study, a CT will be done before surgery
and serological bone turnover markers will be collected
(SCTx and P1NP). In a case of withdrawal of full consent,
the subject will be followed according to the routine stand-
ard follow-up of THA patients at our institution, including
regular clinical examinations and radiographic follow-up
visit at the operating surgeon every 2–3 years.
Fig. 1 3D-CT = Three-dimensional volumetric computed tomography, DxV = DXA scan vertebrae L1-L4, Rad = Anterioposterior and lateral radiographs,
Clin = clinical follow-up including Harris hip score, EQ-5D, Activity scores and Pain Numerical Rating Scale, Ser = serological markers of bone turnover
markers, Sta = standard blood test, Adm=Administration of IMP/placebo, AE = AE/SAE assessment, Cal = S-Calcium
Sköldenberg et al. BMC Musculoskeletal Disorders  (2016) 17:174 Page 3 of 10
Table 1 Detailed inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age 40–85 years For women of childbearing potential: Subject refuses to use 1 highly effective
method of contraception (contraceptive pill, intra uterine contraceptive device)
for the duration of the study and for 10 months after the last dose of study
medication.
Short Portable Mental Status Questionnaire (SPMSQ) also named
Pfeiffertest ≥7
For males with a partner of childbearing potential: Subject refuses to use 1
highly effective method of contraception for the duration of the study and for
10 months after the last dose of study medication.
Male and females For males with a partner who is pregnant: Subject refuses to use a condom for
the duration of the study and for 10 months after the last dose of study
medication.
The primary THA performed between 7 to 20 years before inclusion. Pain in the operated hip (because the presence of hip pain in combination
with an osteolytic lesion is an indication for revision surgery). VAS >3
The primary THA performed due to osteoarthritis or congenital
dysplasia of the hip.
Previous revision surgery of the hip i.e. exchange of any inplant after the
primary surgery
Uncemented cup fixation Inflammatory arthritis
Baseline osteolytic lesion of at least 4 cm3 and at most 40 cm3
around an uncemented acetabular component with a
polyethylene liner.
Previous participation in clinical trials with denosumab or administration of
commercial denosumab (Prolia™ or Xgeva™)
Participant is willing and able to follow study protocol and has
provided informed consent prior to any study specific procedures.
Currently enrolled in or has not yet completed at least 1 month since ending
other investigational device or drug trial (s), or subject is receiving other
investigational agent (s).
Treatment with any intravenous bisphosphonate, fluoride (except for dental
treatment) or strontium ranelate within 5 years prior to inclusion.
Treatment with any oral bisphosphonate within 1 year prior to inclusion.
Treatment with cortisol or cytostatic drugs within 6 months prior to inclusion.
Administration of any of the following treatments 3 months prior to screening:
For women of childbearing potential: Subject refuses to use 1 highly effective
method of contraception (contraceptive pill, intra uterine contraceptive device)
for the duration of the study and for 10 months after the last dose of study
medication.
For males with a partner of childbearing potential: Subject refuses to use 1
highly effective method of contraception for the duration of the study and for
10 months after the last dose of study medication.
For males with a partner who is pregnant: Subject refuses to use a condom for
the duration of the study and for 10 months after the last dose of study
medication.
Pain in the operated hip (because the presence of hip pain in combination
with an osteolytic lesion is an indication for revision surgery). VAS >3
Previous revision surgery of the hip i.e. exchange of any inplant after the
primary surgery
Inflammatory arthritis
Previous participation in clinical trials with denosumab or administration of
commercial denosumab (Prolia™ or Xgeva™)
Currently enrolled in or has not yet completed at least 1 month since ending
other investigational device or drug trial (s), or subject is receiving other
investigational agent (s).
Treatment with any intravenous bisphosphonate, fluoride (except for dental
treatment) or strontium ranelate within 5 years prior to inclusion.
Treatment with any oral bisphosphonate within 1 year prior to inclusion.
Treatment with cortisol or cytostatic drugs within 6 months prior to inclusion.
Administration of any of the following treatments 3 months prior to screening:
Anabolic steroids or testosterone
Glucocorticosteroids (≥5 mg prednisone equivalent per day for more than
10 days or a total cumulative dose of≥ 50 mg)
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Table 1 Detailed inclusion and exclusion criteria (Continued)
Calcitonin
Calcitriol or vitamin D derivatives [vitamin D contained in supplements or
multivitamins is allowed]
Other bone active drugs including anti-convulsives (except benzodiazepines)
and heparin
Chronic systemic ketoconazole, ACTH (adrenocorticotrophic hormone), cinacalcet,




Bone metabolic disorders (such as OI, PHPT, Paget)
History of osteonecrosis of the jaw and/or recent tooth extraction or dental
surgery; or planned invasive dental proceedures during the study
Serum 25-OH D <20 ng/ml
Significant malabsorption including Celiac Disease, Short Bowel Syndrome,
Crohn’s Disease, Previous Gastric Bypass.
Active cancer and/or malignancy in last 5 years (except cervical carcinoma in
situ or basal cell carcinoma)
History of solid organ or bone marrow transplant.
Hypersensitivity to any components of study drug.
Intolerance to calcium supplements.
Pregnancy and/or currently lactating.
Significantly impaired renal function as determined by a derived glomerular
filtration rate (GFR) using Cockcroft Gault formula of ≤ 30 mL/min/1.73 m2
Elevated transaminases ≥ 2.0 × upper limit of normal (ULN); Elevated total
bilirubin (TBL) > 1.5 × ULN.
Any condition or illness (acute, chronic, or history), which in the opinion of the
Investigator might interfere with the evaluation of efficacy and safety during
the study or may otherwise compromise the safety of the subject.
Hypocalcaemia.
Bone metabolic disorders (such as OI, PHPT, Paget)
History of osteonecrosis of the jaw and/or recent tooth extraction or dental
surgery; or planned invasive dental proceedures during the study
Serum 25-OH D <20 ng/ml
Significant malabsorption including Celiac Disease, Short Bowel Syndrome,
Crohn’s Disease, Previous Gastric Bypass.
Active cancer and/or malignancy in last 5 years (except cervical carcinoma in
situ or basal cell carcinoma)
History of solid organ or bone marrow transplant.
Hypersensitivity to any components of study drug.
Intolerance to calcium supplements.
Pregnancy and/or currently lactating.
Significantly impaired renal function as determined by a derived glomerular
filtration rate (GFR) using Cockcroft Gault formula of ≤ 30 mL/min/1.73 m2
Elevated transaminases ≥ 2.0 × upper limit of normal (ULN); Elevated total
bilirubin (TBL) > 1.5 × ULN.
Any condition or illness (acute, chronic, or history), which in the opinion of the
Investigator might interfere with the evaluation of efficacy and safety during
the study or may otherwise compromise the safety of the subject.
Sköldenberg et al. BMC Musculoskeletal Disorders  (2016) 17:174 Page 5 of 10
Endpoints and follow-up
The primary endpoint variable will be the change in volume
of the osteolytic lesion over 3 years (measured with 3D-CT
in cm3):
Efficacy3years ¼ Volume3years−Volumebaseline:
Secondary endpoints include change in volume of the
osteolytic lesion over 2 years, percentage change of the
lesion over the study period, clinical outcome scores and
bone turnover measurements (Table 2). Depending on
the outcome parameters, measurements will take place
at screening, 6, 12, 18, 24, 30 and 36 months (Fig. 1).
Osteolysis assessment
We will use a high-resolution three dimensional computed
tomography (3D-CT) at inclusion to detect and measure
the volume of the osteolysis according to Howie et al.
[13, 30]. The scan will be repeated at 2 and 3 years. Oste-
olysis will be defined as a demarcated nonlinear osteolytic
lesion >3 mm. The measurements will be performed by a
technician otherwise not involved in the study and blinded
to treatment and who is trained in quantitative CT analysis.
3D-CT has been shown to have an 80 % sensitivity and a
100 % specificity in detecting osteolytic lesions [12] around
uncemented acetabular components. Once detected the
volume of the lesion can be measured with an error of
mean (SD) 7.1 % ±24.1 % (0.3 ± 1.1 cm3) [12].
Radiological and bone densitometric assessment
Plain x-rays of the hip and femur will be taken at baseline
and at 3 years to measure wear of the polyethylene. The
two-dimensional (2-D) linear head penetration rate will be
measure measured from the postoperative examination and
inclusion examination using the software Hip Analysis
Suite™ (University of Chicago, Chicago, Illinois, USA) ver-
sion 8.0.4.1 [31] This method uses conventional AP radio-
graphs and the software uses image analysis techniques,
determination of bone landmarks and edge detection algo-
rithms to determine the 2-D penetration value change in
the position of the femoral head centre with respect to the
acetabular component centre. The radiographs will also be
examined at 3 years for signs of atypical femoral fractures.
There are three reported cases of atypical femoral fractures
after denosumab treatment but all of those had, prior to
denosumab treatment, been treated with long-term bis-
phosphonate treatment [32–34]. Bone mineral density
(BMD) of the lumbar spine (vertebrae L1 through L4) will
be measured at inclusion and at 3 years using dual x-ray ab-
sorptiometry (DXA) (DPX-L; Lunar, Madison, Wisconsin,
USA) The BMD will be categorized according to the World
Health Organization (WHO) classification for osteoporosis.
Clinical safety assessments and withdrawal from study
Adverse events (AEs) are defined as any untoward medical
occurrence in a patient or clinical investigation subject
administered a pharmaceutical product and that does not
necessarily have a causal relationship with this treatment.
Adverse events include serious adverse events (SAEs), ad-
verse drug reactions (ADRs), serious adverse drug reactions
(SADRs) and will be assessed throughout the study period
for all patients (Table 3). In case of an adverse event, or
serious adverse events, treatment and follow-up will be
performed according to clinical routine. The investigator
will ensure that all events observed by the investigator or
reported by the subject that occur throughout the trial
period, starting from the time when a subject has signed
the informed consent through to 30 days after the last
dose of IP or the EOS (excluding the long-term follow-up
period) which ever is longer, are reported using the applic-
able CRF and properly captured in the patients’ medical
records. The investigator will record and grade all adverse
events according to Table 3. The investigator will assess
whether the adverse event is possibly related to the IP.
This relationship is indicated by a response to the ques-
tion: “Is there a reasonable possibility that the event may
be related to a study activity”? The investigator will
review laboratory test results and determining whether
an abnormal value in a trial subject represents a change
from the subject’s baseline values. Abnormal laboratory
Table 2 Secondary endpoints
No. Outcome measurement Follow-up time
1 Baseline data including height, weight,
medical history, physical examination
Screening




3. Pain Numerical Rating Scale (PNRS), Activity




4a Percent change from baseline in BMD
in vertebrae L1-L4 measured with dual-
energy x-ray absorptiometry (DXA)
Screening, 36
months
5. Correlation between change in bone
turnover markers and progression of
osteolysis. Serum C-terminal telopeptide
of type I collagen (SCTx) [42] and
procollagen type 1 amino-
terminal propeptide (P1NP) [43].
Screening, 12, 24,
36 months
6. Correlation between change in serum
concentrate values for RANKL and




7. Occurrence of adverse events 6, 12, 18, 24, 30,
36 months
8. Radiological analysis plain x-ray Screening, 36
months
aPrevious studies on denosumab have focused on patients with osteoporosis
or other metabolic bone disease and it is to be expected that the patients in
this trial will have a normal bone mass
bSerum levels of RANKL and OPG will be quantified by ELISA with
commercially available matched antibodies [44, 45]
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findings without clinical significance (based on the investi-
gator’s judgment) will not be recorded as adverse events. A
patient may also voluntarily withdraw from treatment due
to what he or she perceives as an intolerable adverse event.
If either of these situations arises, the patient should be
strongly encouraged to undergo an end-of-study assess-
ment and be under medical supervision until symptoms
cease or the condition becomes stable.
Functional outcome
The Harris hip score (HHS) and WOMAC score will be
used to assess patient-reported functional hip status, and
physical activity [35, 36]. Health-related quality of life will
be assessed by the EQ-5D (EuroQoL), which uses five
dimensions: mobility, self-care, usual activity, pain/discom-
fort and anxiety/depression [37]. Each dimension is divided
into three levels as follows: 1, no problems; 2, some prob-
lems; and 3, extreme problems. This generates 243 different
‘health states’ and the EQ-5D index score. Pain from the
hip will be recorded using the Pain Numeric Rating Scale
(PNRS), which is an 11-point (0 to 10) scale, in which 0
denotes no pain and 10 unbearable pain [38].
Data quality assurance
The study progress and study conduct will be monitored
before, during and after the study to ensure that ICH-
GCP, regulatory requirements, and all aspects of the
protocol are followed. The medical records and other
documents will be reviewed for verification of agreement
with data on the Case Report Forms (CRFs). The subject
has a right for a protection against invasion of privacy.
All study data will be collected and managed in a digital
CRF using REDCap electronic data capture tools hosted
at Karolinska Institutet [39]. REDCap (Research Elec-
tronic Data Capture) is a secure, web-based application
designed to support data capture for research studies,
Table 3 Definition of safety assessments
No. Type Definition
1. Adverse event (AE) An adverse event is defined in the International Conference on Harmonization (ICH) Guideline for Good Clinical
Practice as “any untoward medical occurrence in a patient or clinical investigation subject administered a
pharmaceutical product and that does not necessarily have a causal relationship with this treatment.” (ICH E6:1.2).
The investigator is responsible for reviewing laboratory test results and determining whether an abnormal value in
an individual study subject represents a change from values before the study. In general, abnormal laboratory
findings without clinical significance (based on the investigator’s judgment) should not be recorded as adverse




A serious adverse event (SAE) is defined as an adverse event that meets at least 1 of the following criteria: a) fatal, b)
life threatening (places the subject at immediate risk of death), c) requires in-patient hospitalization or prolongation of
existing hospitalization, d) results in persistent or significant disability/incapacity or congenital anomaly/birth defect e)
other significant medical hazard. A hospitalization meeting the regulatory definition for “serious” is any inpatient hospital
admission that includes a minimum of an overnight stay in a health care facility. Any adverse event that does not meet
one of the definitions of serious (e.g., emergency room visit, outpatient surgery, or requires urgent investigation) may be
considered by the investigator to meet the “other significant medical hazard” criterion for classification as a serious
adverse event. Examples include allergic bronchospasm, convulsions, and blood dyscrasias.
3. Adverse drug
reaction (ADR)
All untoward and unintended responses to a medicinal product related to any dose administered. The phrase
“responses to a medicinal product” means that a causal relationship between the medicinal product and the
adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out.
4. Serious adverse drug
reaction (SADR)
A serious ADR (SADR) is an ADR that meets the definition of SAE
5. AE attributes The investigator will assign the following adverse event attributes:
Adverse event diagnosis or syndrome (s), if known (if not known, signs or symptoms)
Dates of onset and resolution
Severity
Assessment of relatedness to IP
Action taken.
6 AE grading The following adverse events severity grading scale used in the trial.
MILD: Aware of sign or symptom, but easily tolerated
MODERATE: Discomfort enough to cause interference with usual activity
SEVERE: Incapacitating with inability to work or do usual activity
LIFE-THREATENING: Refers to an event in which the patient was, in the view of the investigator, at risk of death at
the time of event.
FATAL
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providing: 1) an intuitive interface for validated data entry;
2) audit trails for tracking data manipulation and export
procedures; 3) automated export procedures for seamless
data downloads to common statistical packages; and 4)
procedures for importing data from external sources. In
this study, each subject will receive a unique identification
number, which will be linked to the CRF. The data will
then be blinded correspondingly in all data analyses. How-
ever, the study monitor, auditor, representative from any
Regulatory Authority, as well as the appropriate Ethical
Committee are permitted to review the subject’s primary
medical records including laboratory test result reports,
ECG reports, admission and discharge summaries, AE
and SAE reports occurring during the study.
Sample size
Assumptions for sample size
In a pilot study using 3D-CT Schwarz et al. [40] identified
19 patients with osteolytic lesions around an uncemented
acetabular cup used in THA. After 1 year the volume of
the lesions had increased with mean (SD) 3.19 (3.67) cm3.
Howie et al. [14] studied the natural progression of osteo-
lytic lesions after THA with 3D-CT. He scanned 30 pa-
tients with a known osteolytic lesion 15 months (range,
12–27) after the initial scan and found that 16 (53 %) of
the lesions had increased in volume. The lesions most
likely to increase in size was ≥10 cm3 at the initial scan.
The median volume increase was 3 cm3 during the
15 months studied. Based on the work by Schwarz [40]
and Howie [14] and thereby assuming a 3 cm3 increase
annually and a 3 year study period would indicate that we
are looking for a mean increase of 9 cm3 with a SD of
8 cm3 [14]. The SD is estimated by dividing Howie et al.’s
range of lesion size divided by 4 as suggested by Hozo et
al. [41]. For denosumab we assume that it will reduce the
progression of osteolysis about 50 % compared to placebo.
Patients treated with denosumab would therefore have a
mean increase of 4.5 cm3 (0.5 × 9 cm3) after 3 years.
Sample size calculation
A two-tailed superiority sample size calculation for the
primary endpoint variable change in osteolytic volume after
3 years, assuming a progression of volume of 9 cm3 for the
placebo and 4.5 cm3 for the denosumab group and with a
SD of 8 cm3 in both groups and a p-value of 0.05 means 50
subjects in each group for a 80 % power. We will include
55 patients in each group to allow for loss to follow-up and
loss of data. We therefore need to identify 110 patients with
osteolytic lesions and include them in the study.
Statistics
The analyses will be performed on the basis of the
intention-to-treat principle, and all patients who receive
at least one injection of either denosumab or placebo will
be included in the final analysis. We will use the unpaired
Student’s t-test and Levene’s test for comparison of change
in osteolysis volume at 2 and 3 years. Descriptive statistics
(means and standard deviations) will be used to describe
the patient characteristics and outcome variables at the
measurement points. An analysis of covariance (ANCOVA)
of the primary endpoint including terms for treatment
group, stratification factors and with age and sex as con-
founders will be performed. ANCOVA will also be used for
numeric secondary outcome variables such as progression
of osteolysis at 2 years, change in vertebrae 1–4 BMD and
the contralateral hip and biochemical markers of bone
turnover. For hip-specific outcomes score (Harris hip score,
WOMAC) and health-related quality of life (EQ-5D) we
will use non-parametric tests. For subjects that withdrawn
from the study before year 3 the data from the last observa-
tion will be carried forward (imputed). Safety data will be
summarized with descriptive statistics.
Discussion
This is the first study on denosumab and osteolysis. We
will include patients with asymptomatically osteolytic le-
sions. These lesions are, based on the current literature,
highly likely to progress over the years and lead to massive
osteolysis and require revision surgery. Revision surgery is
significantly more risky for the individual patient than a
primary THA. The risk of dislocation and deep peripros-
thetic joint infection is, for example, 4–10 times more
common after revision arthroplasty than after a primary
THA. The clinical outcome regarding hip function is also
poorer after revision surgery. Although our proposed
main outcome is volume of osteolysis and not a clinical
endpoint, the study is designed as a proof-of-concept and
the results, if positive, could be inferred to larger patient
groups.
The risks of denosumab treatments are low, the side-
effects reported are benign. There are two reported cases
of atypical femoral fractures after denosumab treatment
but all of those had, prior to denosumab treatment, been
treated with long-term bisphosphonate treatment. Any
previous bisphosphonate treatment is an exclusion cri-
teria in the current trial. In summary, we believe the
benefit of the trial outweighs the risk for the individual
patient.
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